查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992922

犬類關節炎市場：2026-2032年全球市場預測（依治療方法、藥物類別、給藥途徑、最終用戶和分銷管道分類）

Canine Arthritis Market by Treatment Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，犬類關節炎市場價值將達到 20.8 億美元，到 2026 年將成長至 22.7 億美元，到 2032 年將達到 36.7 億美元，複合年成長率為 8.39%。

主要市場統計數據
基準年 2025 20.8億美元
預計年份：2026年 22.7億美元
預測年份：2032年 36.7億美元
複合年成長率 (%) 8.39%

本書簡明扼要、權威地介紹了正在重新定義犬類關節炎管理和相關人員優先事項的臨床、商業和看護者趨勢。

犬類關節炎已從單純的臨床問題演變為一項多方面的挑戰，需要臨床醫生、產品開發人員、保險公司和飼主共同合作。儘管疼痛管理和關節保護等長期存在的臨床難題依然是核心，但介入措施的選擇和實施方式已發生巨大變化。獸醫必須平衡飼主對生活品質的期望、能夠改變疾病進程的新治療方案，以及精通數位科技的寵物飼主對透明證據和便捷治療方案的需求。因此，成功的策略必須將臨床療效與實際用藥依從性、經濟性和支持慢性病管理的醫療服務模式結合。

科學、消費者行為和護理服務的重大變革正在重新定義犬類關節炎的治療管道和經營模式。

犬類關節炎的治療格局正在經歷一場變革，其驅動力包括科學創新、飼主期望的轉變以及醫療服務模式的演變。在科學領域，靶向單株抗體和改良型緩解疾病藥物的出現，正將治療重點從單純緩解症狀轉向針對潛在病理的干涉。這些進展催生了新的臨床途徑，並促使獸醫重新評估沿用已久的治療流程。此外，從遠端醫療諮詢到穿戴式活動監測器等技術的融合，使得對運動功能和治療反應的持續評估成為可能，從而提高了治療的個人化程度，並有助於製定長期治療策略。

基於證據的分析，探討 2025 年美國關稅調整將如何重塑整個犬類關節炎護理過程中的採購、定價和供應韌性。

2025年實施的關稅措施的累積影響波及犬類關節炎護理價值鏈的各個環節，包括採購、定價和策略採購決策。某些藥品原料、進口成品和專用復健設備的關稅提高，增加了接收成本，並擾亂了採購計畫。為此，製造商和經銷商正在加強對供應鏈多元化的審查，並評估諸如近岸外包、供應商整合以及使用臨床上可接受的國產組件等方案。雖然這些調整可以降低風險，但也需要重新分配資金，並調整與經銷商和獸醫合作夥伴的合約條款。

透過整合治療方法、藥物分類、給藥途徑、分銷管道、最終用戶和公司定位的綜合細分分析，揭示了治療引入的管道。

細分市場洞察揭示了治療方法選擇、藥理學、給藥途徑、分銷、終端用戶和公司策略如何相互交織並塑造護理模式。根據治療類型，市場可細分為輔助療法、非藥物療法和藥物療法。輔助療法包括營養補充劑和膳食補充劑，其中膳食補充劑類別還包括軟骨素、葡萄糖胺和ω脂肪酸。非藥物療法包括針灸、雷射療法和物理療法，其中物理療法又分為水療和物理療法。另一方面，藥物療法包括緩解疾病劑、單株抗體和非類固醇消炎劑）。緩解疾病劑的特徵成分包括透明質酸和多硫酸Glico，單株抗體的代表藥物是貝得必單抗，而非類固醇消炎劑包括卡洛芬、德拉考昔和美洛昔康。從藥物分類來看，將骨關節炎緩解疾病治療藥物、單株抗體和非類固醇消炎劑）進行分類，再次印證了臨床治療重點向緩解疾病和標靶生技藥品的轉變。玻尿酸和多硫酸Glico構成了前一類藥物的基礎，其中貝得妥單抗為抗體療法提供了明確的基準；而卡洛芬、德拉考昔和美洛昔康則是常用的NSAIDs。

影響美洲、歐洲、中東、非洲和亞太地區招募、存取和商業化策略的關鍵區域趨勢和市場進入考量。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的科研重點、監管管道和商業性模式有著顯著影響，每個區域都擁有獨特的流行病學特徵和醫療保健系統。在美洲，寵物擁有率高和獸醫基礎設施完善推動了新療法和綜合護理模式的快速普及，而直接面對消費者的數位化管道和強大的專科診所網路則支持了多樣化治療方法和復健服務的引入。相較之下，在歐洲、中東和非洲，法規結構的差異以及高成本生技藥品取得途徑的不同，造就了不同的市場細分，在這些細分市場中，國產製劑和經濟實惠的輔助療法往往更受歡迎。

主要企業簡介和策略定位說明了規模、專業化以及對研發的關注如何在犬類關節炎生態系統中創造競爭優勢。

公司層面的定位展現了規模、產品線組成和商業性能力如何決定犬關節炎領域的競爭優勢。德克拉（Dechra）以專注於動物醫藥和以客戶為中心的經銷策略而聞名，該策略旨在加強與臨床決策者的關係。禮來（Elanco）利用其廣泛的產品組合和全球影響力，支持整合產品部署，並與學術和臨床機構進行合作夥伴關係。碩騰（Zoetis）將先進的研發能力與龐大的銷售團隊和臨床醫學教育計畫相結合，以推動產品在臨床實踐中的應用和上市後證據的生成。每家公司都體現了不同的策略原型：專業執行、多元化產品組合的優勢以及規模驅動的臨床影響力。

產業領導者採用的實用且優先的建議，旨在協調臨床證據、綜合護理路徑和供應鏈韌性，以確保永續的競爭優勢。

針對領導者的具體建議著重於協調臨床價值、商業性可行性和營運韌性，以掌握長期機會。首先，優先生成能夠反映多方面治療方法比較、長期安全性和真實世界結果的證據，確保臨床試驗和上市後監測的設計能夠得出與真實世界相關的終點指標。其次，投資於整合藥物治療、非藥物治療和支持服務的綜合護理路徑，並將這些項目與數位化工具結合，以簡化患者參與度和用藥依從性的監測。第三，透過採購多元化、評估近岸外包方案以及製定進口原料緊急時應對計畫來增強供應鏈韌性，從而降低關稅和進口波動風險。

為了提供實際的見解，我們採用了一種高度透明的調查方法，結合了對臨床醫生的初步訪談、對臨床和監管方面的二次研究以及分析三角驗證。

本執行摘要的研究結合了定性和定量方法，以確保分析的穩健性和多角度性。主要研究包括對獸醫、診所管理人員和行業高管進行結構化訪談，以了解臨床實踐模式、應用促進因素和商業優先事項。次要研究涉及對同行評審的臨床文獻、監管指南、上市公司資訊披露和產品說明的審查，以支持研究結果並為技術進步提供背景資訊。此外，還進行了比較分析，以根據觀察到的應用趨勢，梳理治療機制、給藥途徑和分銷管道的經濟效益。

具有前瞻性的結論，整合了臨床進展、營運挑戰和策略問題，需要進行調整以改善犬關節炎的治療效果。

總之，犬類關節炎是一個充滿活力的領域，科學進步、飼主期望和商業性現實相互交織，既帶來了複雜性，也帶來了機會。緩解疾病藥物和標靶生技藥品的成熟有望將治療模式轉向長期關節健康，同時，非藥物療法和輔助療法也日益被認為是多方面護理的重要組成部分。區域和政策因素，例如關稅變化和分銷管道的演變，帶來了營運方面的挑戰，需要積極主動的供應鏈和定價策略。在這種環境下取得成功，需要相關人員投資於切實可行的商業化模式，優先考慮嚴格的證據生成、與臨床醫生的合作以及真實世界的治療效果和飼主的依從性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：犬類關節炎市場：依治療方法

  • 輔助療法
    • 營養補充品
    • 補充
      • 軟骨素
      • 葡萄糖胺
      • 歐米伽脂肪酸
  • 非藥物療法
    • 針刺
    • 雷射療法
    • 物理治療
      • 水療法
      • 物理治療
  • 藥物治療
    • 緩解疾病藥物
      • 玻尿酸
      • 多硫酸Glico聚醣
    • 單株抗體
    • 非類固醇消炎劑
      • 卡洛芬
      • 德拉考昔
      • 美洛昔康

第9章：犬類關節炎市場：依藥物類別分類

  • 骨關節炎的治療
    • 玻尿酸
    • 多硫酸Glico聚醣
  • 單株抗體
  • 非類固醇消炎劑
    • 卡洛芬
    • 德拉考昔
    • 美洛昔康

第10章：犬類關節炎市場：依給藥途徑分類

  • 注射
  • 口服
  • 外用

第11章：犬類關節炎市場：依最終用戶分類

  • 動物診所
  • 動物醫院

第12章：犬類關節炎市場：依通路分類

  • 線上
  • 離線

第13章：犬類關節炎市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：犬類關節炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：犬類關節炎市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國犬類關節炎市場

第17章：中國犬類關節炎市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • American Regent, Inc.
  • Aratana Therapeutics, Inc.
  • Bayer Animal Health GmbH
  • Bimeda Holdings PLC
  • Boehringer Ingelheim Vetmedica GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation
  • Indian Immunologicals Limited
  • Innovet Pet Products, Inc.
  • Kemin Industries, Inc.
  • Merck Animal Health
  • Neogen Corporation
  • Norbrook Laboratories Limited
  • Nutramax Laboratories, Inc.
  • Ourofino Saude Animal Participacoes SA
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • VetPlus Ltd.
  • VetriScience Laboratories
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-1A1A064C0106

The Canine Arthritis Market was valued at USD 2.08 billion in 2025 and is projected to grow to USD 2.27 billion in 2026, with a CAGR of 8.39%, reaching USD 3.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.08 billion
Estimated Year [2026] USD 2.27 billion
Forecast Year [2032] USD 3.67 billion
CAGR (%) 8.39%

A concise and authoritative introduction to the evolving clinical, commercial, and caregiver dynamics that are redefining canine arthritis management and stakeholder priorities

Canine arthritis has evolved from a narrowly clinical concern into a multifaceted challenge that demands integrated responses from clinicians, product developers, payors, and caregivers. Longstanding clinical imperatives such as pain control and joint preservation remain central, yet the context in which interventions are selected and delivered has shifted dramatically. Veterinary practitioners are balancing owner expectations for quality of life, emerging therapeutic classes that alter disease trajectory, and an increasingly digital-savvy pet owner population that seeks transparent evidence and convenient access to treatments. As a result, successful strategies must bridge clinical efficacy with real-world adherence, affordability, and service delivery models that support chronic disease management.

In parallel, research and innovation are broadening the therapeutic toolkit available to veterinarians and owners. Novel biologics and targeted therapies are being integrated alongside established pharmacological agents and a resurgent interest in nonpharmacological modalities. This plurality of options elevates the importance of comparative clinical evidence, practical guidelines for multimodal care, and communication strategies that synthesize risk-benefit profiles for diverse patient cohorts. Consequently, stakeholders must approach canine arthritis not only as a medical condition but as an ecosystem that includes preventive care, rehabilitation, nutritional strategies, and digital monitoring.

Compelling transformative shifts in science, consumer behavior, and care delivery that are redefining treatment pathways and commercial models for canine arthritis

The landscape of canine arthritis is undergoing transformative shifts driven by scientific innovation, changing client expectations, and evolving care delivery models. On the scientific front, the emergence of targeted monoclonal antibodies and refined disease modifying agents has redirected attention toward interventions that address underlying pathology rather than only symptomatic relief. These advances are catalyzing new clinical pathways and prompting veterinary clinicians to reassess long-standing treatment algorithms. Furthermore, technological integration-ranging from telehealth consultations to wearable activity monitors-enables continuous assessment of mobility and treatment response, thereby improving personalization of care and informing long-term therapeutic decisions.

Concurrently, client expectations are reshaping market dynamics. Pet owners increasingly evaluate treatment options through the lens of long-term outcomes, safety profiles, and convenience. This shift elevates the role of complementary therapies and rehabilitation services as acceptable components of multimodal regimens. Finally, commercial and regulatory pressures are prompting manufacturers and distributors to rethink supply chain resilience and pricing strategies. As stakeholders adapt, the industry is moving toward integrated care models that combine pharmacological therapies, nonpharmacological interventions, and owner-centered support to optimize outcomes across diverse canine populations.

An evidence-oriented analysis of how United States tariff adjustments in twenty twenty five are reshaping procurement, pricing, and supply resilience across canine arthritis care pathways

The cumulative impact of tariffs implemented in the United States in twenty twenty five reverberates across procurement, pricing, and strategic sourcing decisions within the canine arthritis value chain. Tariff escalations on select pharmaceutical ingredients, finished imported formulations, and specialized rehabilitation equipment have increased landed costs and introduced volatility in procurement planning. In response, manufacturers and distributors have intensified scrutiny of supply chain diversification, evaluating alternatives such as nearshoring, vendor consolidation, and substitution with domestically sourced components where clinically acceptable. These adaptations, while mitigating exposure, have required capital reallocation and adjustments to contractual terms with distributors and veterinary partners.

Clinicians and practice managers have observed indirect consequences in the clinic, including tighter inventory management and incremental cost pass-through for certain imported therapeutics or advanced rehabilitation devices. At the same time, the tariff environment has accentuated the competitive advantage of companies with vertically integrated production or established domestic manufacturing footprints, as these players can buffer price increases and maintain supply continuity. Importantly, the policy-induced cost pressures have also stimulated innovation in product formulation and delivery, with stakeholders exploring low-cost manufacturing techniques, reformulation to reduce reliance on affected inputs, and extended-duration therapeutics that reduce frequency of procurement and improve adherence.

Comprehensive segmentation insights integrating treatment modalities, drug classes, administration routes, distribution channels, end users, and company positioning to reveal adoption pathways

Segment-specific insights reveal how treatment choices, pharmacology, administration routes, distribution, end users, and company strategies intersect to shape care patterns. Based on treatment type, the market divides into complementary therapies, nonpharmacological therapies, and pharmacological therapies, where complementary therapies encompass nutraceuticals and supplements and the supplements category further includes chondroitin, glucosamine, and omega fatty acids; nonpharmacological therapies encompass acupuncture, laser therapy, and physical therapy with physical therapy branching into hydrotherapy and physiotherapy, while pharmacological therapies include disease modifying agents, monoclonal antibodies, and nonsteroidal anti inflammatory drugs, the disease modifying agents further characterized by hyaluronic acid and polysulfated glycosaminoglycan, monoclonal antibodies represented by bedinvetmab, and nonsteroidal anti inflammatory drugs exemplified by carprofen, deracoxib, and meloxicam. Based on drug class, the breakdown into disease modifying osteoarthritic agents, monoclonal antibodies, and nonsteroidal anti inflammatory drugs reiterates the clinical pivot toward disease modification and targeted biologics, with hyaluronic acid and polysulfated glycosaminoglycan anchoring the former category and bedinvetmab providing a clear reference point for antibody therapies while carprofen, deracoxib, and meloxicam represent commonly used NSAIDs.

Based on route of administration, injectable, oral, and topical formats frame clinical decision making, with injectable options often delivered subcutaneously and oral therapies typically administered in tablet or capsule form while topical preparations are commonly available in gel formulations. Based on distribution channel, online pharmacies, pet specialty stores, retail pharmacies, and veterinary hospital pharmacies define access pathways, with online channels segmented between general e commerce platforms and specialized veterinary e commerce platforms that influence adherence and price transparency. Based on end user, specialty pet clinics, veterinary clinics, and veterinary hospitals reflect where care is delivered; specialty pet clinics frequently include rehabilitation centers, veterinary clinics can be divided into general practice and orthopedic clinics, and veterinary hospitals range from multispecialty facilities to small animal hospitals. Based on company, market activity concentrates among established players such as Dechra, Elanco, and Zoetis, each shaping product development, distribution strategies, and clinical education in distinct ways. Taken together, these segmentation frames illuminate where clinical innovation, commercial investment, and practical adoption are converging and where gaps remain for targeted evidence generation and service optimization.

Key regional dynamics and market entry considerations across the Americas, Europe Middle East and Africa, and Asia Pacific that influence adoption, access, and commercialization strategies

Regional dynamics materially influence research priorities, regulatory pathways, and commercial approaches across the Americas, Europe Middle East and Africa, and Asia Pacific, each presenting distinct epidemiological profiles and care delivery ecosystems. In the Americas, high pet ownership rates and advanced veterinary practice infrastructure favor rapid uptake of novel therapeutics and integrated care models, while direct-to-consumer digital channels and robust specialty clinic networks support adoption of multimodal regimens and rehabilitation services. Conversely, Europe Middle East and Africa exhibit heterogeneous regulatory frameworks and variable access to high-cost biologics, which creates differentiated market corridors where domestically produced formulations and cost-effective complementary therapies often find traction.

In the Asia Pacific region, rapid modernization of veterinary services, growing pet-owning middle classes, and expanding online retail ecosystems are accelerating demand for both established pharmaceuticals and innovative modalities, yet distribution complexity and regulatory variance require localized commercialization strategies. Across regions, differences in veterinary workforce capacity, reimbursement norms, and owner willingness to invest in chronic disease management drive divergent adoption curves for advanced therapeutics and supportive services. As a result, regional strategies must be calibrated to local regulatory realities, channel structures, and owner expectations to unlock sustainable growth and meaningful clinical impact.

Key company profiles and strategic positioning that explain how scale, specialization, and R&D focus drive competitive advantage in the canine arthritis ecosystem

Company-level positioning demonstrates how scale, pipeline composition, and commercial capabilities determine competitive advantage in canine arthritis. Dechra is recognized for its focus on specialty veterinary pharmaceuticals and customer-centric distribution strategies that reinforce relationships with clinical decision makers. Elanco leverages a broad portfolio and global reach to support integrated product rollouts and collaborative research partnerships with academic and clinical institutions. Zoetis combines deep R&D capabilities with extensive field sales forces and clinician education programs that drive clinical uptake and post-launch evidence generation. Together, these companies exemplify different strategic archetypes: specialized specialty-focused execution, diversified portfolio leverage, and scale-driven clinical influence.

Beyond these leading players, a range of smaller innovators and contract manufacturers contribute to category evolution by introducing novel formulations, digital monitoring tools, and localized manufacturing partnerships. Strategic collaborations among incumbents and niche technology providers are increasingly important for translating biologic advances into scalable clinical solutions. For industry stakeholders, identifying the role each company plays in the distribution ecosystem and clinical education landscape informs partnership strategies, competitive benchmarking, and tactical investment decisions.

Practical and prioritized recommendations for industry leaders to align clinical evidence, integrated care pathways, and supply chain resilience for sustained competitive advantage

Actionable recommendations for leaders focus on aligning clinical value, commercial feasibility, and operational resilience to capture long term opportunity. First, prioritize evidence generation that addresses comparative effectiveness, long term safety, and real world outcomes for multimodal regimens, ensuring that clinical trials and postmarket studies are designed to produce practice-relevant endpoints. Second, invest in integrated care pathways that combine pharmacological, nonpharmacological, and supportive services, and pair these programs with digital tools that simplify owner engagement and adherence monitoring. Third, fortify supply chain resilience by diversifying sourcing, evaluating nearshoring options, and developing contingency plans for imported inputs to mitigate tariff and import volatility.

In addition, cultivate deep clinician partnerships through continuing education, practical toolkits for multimodal therapy implementation, and co developed case registries that accelerate learning. Align commercial strategies with regional realities by tailoring pricing, channel mix, and regulatory engagement to local market dynamics. Finally, assess strategic collaborations with smaller innovators and service providers to accelerate time to market for differentiated offerings while leveraging incumbents' distribution and clinician education capabilities. Implementing these recommendations will strengthen competitive positioning and improve care outcomes across diverse clinical and commercial contexts.

A transparent research methodology combining primary clinician interviews, secondary clinical and regulatory review, and analytical triangulation to support actionable insights

The research underpinning this executive summary combines qualitative and quantitative approaches to ensure robust, multiperspective analysis. Primary research included structured interviews with veterinary clinicians, practice managers, and industry executives to capture clinical practice patterns, adoption drivers, and commercial priorities. Secondary research reviewed peer reviewed clinical literature, regulatory guidance, public company disclosures, and product monographs to corroborate findings and contextualize technological trajectories. Comparative analyses were performed to map therapeutic mechanisms, administration routes, and distribution channel economics against observed adoption trends.

Analytical methods encompassed thematic synthesis of interview data, cross validation of product and company claims with regulatory filings and clinical trial registries, and scenario analysis to evaluate the operational impacts of supply chain and policy shifts. Throughout the process, emphasis was placed on triangulation between clinician experience, commercial intelligence, and documented clinical evidence to reduce bias and strengthen practical relevance. The methodology supports actionable insights by focusing on implementation barriers, evidence gaps, and strategic levers that stakeholders can operationalize within their organizations.

A forward-looking conclusion synthesizing clinical advances, operational challenges, and strategic imperatives that must be reconciled to improve canine arthritis outcomes

In conclusion, canine arthritis represents a dynamic area where scientific advances, client expectations, and commercial realities intersect to create both complexity and opportunity. The maturation of disease modifying agents and targeted biologics offers the potential to shift treatment paradigms toward longer term joint health, while nonpharmacological and complementary therapies are increasingly recognized as essential components of multimodal care. Regional and policy variables, such as tariff changes and distribution channel evolution, introduce operational challenges that demand proactive supply chain and pricing strategies. Success in this environment will require stakeholders to invest in rigorous evidence generation, clinician engagement, and pragmatic commercialization models that prioritize real world outcomes and owner adherence.

Moving forward, organizations that combine clinical credibility with operational agility and collaborative partnerships will be best positioned to deliver meaningful improvements in canine mobility and quality of life. By aligning research priorities with practical implementation pathways and regional market nuances, stakeholders can convert scientific promise into scalable clinical and commercial outcomes that address both current needs and future opportunities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Arthritis Market, by Treatment Type

  • 8.1. Complementary Therapies
    • 8.1.1. Nutraceuticals
    • 8.1.2. Supplements
      • 8.1.2.1. Chondroitin
      • 8.1.2.2. Glucosamine
      • 8.1.2.3. Omega Fatty Acids
  • 8.2. Non Pharmacological Therapies
    • 8.2.1. Acupuncture
    • 8.2.2. Laser Therapy
    • 8.2.3. Physical Therapy
      • 8.2.3.1. Hydrotherapy
      • 8.2.3.2. Physiotherapy
  • 8.3. Pharmacological Therapies
    • 8.3.1. Disease Modifying Agents
      • 8.3.1.1. Hyaluronic Acid
      • 8.3.1.2. Polysulfated Glycosaminoglycan
    • 8.3.2. Monoclonal Antibodies
    • 8.3.3. Non Steroidal Anti Inflammatory Drugs
      • 8.3.3.1. Carprofen
      • 8.3.3.2. Deracoxib
      • 8.3.3.3. Meloxicam

9. Canine Arthritis Market, by Drug Class

  • 9.1. Disease Modifying Osteoarthritic Agents
    • 9.1.1. Hyaluronic Acid
    • 9.1.2. Polysulfated Glycosaminoglycan
  • 9.2. Monoclonal Antibodies
  • 9.3. Non Steroidal Anti Inflammatory Drugs
    • 9.3.1. Carprofen
    • 9.3.2. Deracoxib
    • 9.3.3. Meloxicam

10. Canine Arthritis Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Canine Arthritis Market, by End User

  • 11.1. Veterinary Clinics
  • 11.2. Veterinary Hospitals

12. Canine Arthritis Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Canine Arthritis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Canine Arthritis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Canine Arthritis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Canine Arthritis Market

17. China Canine Arthritis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. American Regent, Inc.
  • 18.6. Aratana Therapeutics, Inc.
  • 18.7. Bayer Animal Health GmbH
  • 18.8. Bimeda Holdings PLC
  • 18.9. Boehringer Ingelheim Vetmedica GmbH
  • 18.10. Ceva Sante Animale S.A.
  • 18.11. Dechra Pharmaceuticals PLC
  • 18.12. Elanco Animal Health Incorporated
  • 18.13. Heska Corporation
  • 18.14. Indian Immunologicals Limited
  • 18.15. Innovet Pet Products, Inc.
  • 18.16. Kemin Industries, Inc.
  • 18.17. Merck Animal Health
  • 18.18. Neogen Corporation
  • 18.19. Norbrook Laboratories Limited
  • 18.20. Nutramax Laboratories, Inc.
  • 18.21. Ourofino Saude Animal Participacoes S.A.
  • 18.22. Phibro Animal Health Corporation
  • 18.23. Vetoquinol S.A.
  • 18.24. VetPlus Ltd.
  • 18.25. VetriScience Laboratories
  • 18.26. Virbac S.A.
  • 18.27. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE ARTHRITIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANINE ARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANINE ARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANINE ARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. GCC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GCC CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 264. GCC CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. GCC CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 268. GCC CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 269. GCC CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. GCC CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. GCC CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 273. GCC CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. G7 CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. G7 CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. G7 CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 309. G7 CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 310. G7 CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 311. G7 CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. G7 CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 313. G7 CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 314. G7 CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 315. G7 CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 316. G7 CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 317. G7 CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 318. G7 CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. G7 CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. G7 CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLIO